metformin has been researched along with Carcinoma in Situ in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity has been linked to a higher risk of pancreatic cancer." | 5.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| "Metformin inhibited pancreatic cancer initiation, suppressed chronic pancreatitis-induced tumorigenesis, and showed promising therapeutic effect in PDAC." | 3.85 | Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. ( Cao, J; Chen, K; Cheng, L; Duan, W; Gao, L; Jiang, Z; Lei, M; Li, J; Ma, Q; Qian, W; Sun, L; Yan, B; Zhou, C, 2017) |
| "Obesity has been linked to a higher risk of pancreatic cancer." | 1.91 | Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023) |
| "Patients aged 18-65 years with type 2 diabetes mellitus (DM) were evaluated, and cases of AIN were identified." | 1.62 | Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients. ( D'Adamo, CR; Fang, SH; Hsu, AT; Hung, YC; Mavanur, AA; Svoboda, SM; Wolf, JH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, G | 1 |
| Gao, H | 1 |
| Dai, S | 1 |
| Li, M | 1 |
| Gao, Y | 1 |
| Yin, L | 1 |
| Zhang, K | 1 |
| Zhang, J | 1 |
| Jiang, K | 1 |
| Miao, Y | 1 |
| Lu, Z | 1 |
| Acosta-Torres, S | 1 |
| Murdock, T | 1 |
| Matsuno, R | 1 |
| Beavis, AL | 1 |
| Stone, RL | 1 |
| Wethington, SL | 1 |
| Levinson, K | 1 |
| Grumbine, F | 1 |
| Ferriss, JS | 1 |
| Tanner, EJ | 1 |
| Fader, AN | 1 |
| Hsu, AT | 1 |
| Hung, YC | 1 |
| Fang, SH | 1 |
| D'Adamo, CR | 1 |
| Mavanur, AA | 1 |
| Svoboda, SM | 1 |
| Wolf, JH | 1 |
| Chen, K | 1 |
| Qian, W | 1 |
| Jiang, Z | 1 |
| Cheng, L | 1 |
| Li, J | 1 |
| Sun, L | 1 |
| Zhou, C | 1 |
| Gao, L | 1 |
| Lei, M | 1 |
| Yan, B | 1 |
| Cao, J | 1 |
| Duan, W | 1 |
| Ma, Q | 1 |
4 other studies available for metformin and Carcinoma in Situ
| Article | Year |
|---|---|
Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Extracellular Traps; Metfo | 2023 |
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cohort Studies; Endometria | 2020 |
Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients.
Topics: Anus Neoplasms; Carcinoma in Situ; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Metformi | 2021 |
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.
Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Di | 2017 |